JUL 22, 2017 08:24 AM PDT

Scientists Train Immune Cells to Gobble Up Cancer

WRITTEN BY: Xuan Pham

Cancer cells evolved to have cunning strategies to protect themselves against the body’s defenses. One of these strategies involve expressing the “don’t eat me tag” so as to fool immune cells into treating it as healthy cells. But now, scientists have wised up to cancer’s tricks and have re-engineered immune cells to recognize and attack these disguised cancer cells.

Image credit: Pixabay.com

The body is equipped with immune cells that recognize and attack cells that it perceives as foreign invaders. Macrophages are among these fighter cells. Considered the “first responders,” these cells gobble up diseased and foreign bodies to protect the body. Its name derives from the Greek for “big eater.”

Healthy cells protect themselves from the macrophage’s destruction by expressing CD47, a surface protein that serves as a “marker of self.” But because cancer cells are mutated versions of healthy cells, they also express CD47. Thus, instead of attacking cancer cells, macrophages let these invaders go untouched because they’ve been tricked into thinking these cells are part of the normal system.

Knowing this trickery, scientists at the University of Pennsylvania sought to help macrophages better distinguish between healthy and cancerous cells. They did this by blocking the interaction of CD47 to surface proteins on the macrophages, known as SIRPA.

"Our new approach takes young and aggressive macrophages from the bone marrow of a human donor and removes a key safeguard that cancer cells have co-opted to prevent them from being engulfed," said Cory Alvey, the study’s lead author.

But there was a problem. While modified macrophages would recognize cancer cells as foreign and launched attacks on these, it also attacked healthy cells in a similar fashion. Indeed, previous studies in mice showed that blocking the interaction between CD47 and SIRPA did decrease cancer cells. But the mice also lost healthy blood cells, became anemic, and some even died.

To solve this problem, the team introduced antibodies that were specific to cancer cells. These would allow macrophages to zero in on the cancer cells that are now unmasked and targeted.

"Combined with cancer-specific targeting antibodies, these engineered macrophages swarm into solid tumors and rapidly drive regression of human tumors without any measurable toxicity,” said Alvey.

The team showed that with just two injections, dime-sized tumors shrank by 80 percent. Furthermore, the cancer cell count decreased by 100-fold. "The big surprise," said Dennis Discher, "is that injected macrophages circulate all around the body but accumulate only within the tumors where they engorge on cancer cells." Discher is a professor in Penn Engineering's Department of Chemical and Bimolecular Engineering, and the study’s senior author.

"Safety thus far is likely a consequence of both the relatively small number of engineered macrophages that are injected and their sequestration into the tumors, away from most healthy cells," Discher said.

“The first phase of clinical trials are tests of human safety, so this is a promising start," Alvey said. "The potency of these engineered macrophages is relatively clear, but the crucial issue is how to maximize the anticancer effects while minimizing side effects, namely the engulfment of normal cells." In addition, the team is working to make the anticancer effects longer-lasting.

Additional sources: University of Pennsylvania

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 16, 2019
Cancer
OCT 16, 2019
New anticancer agent discovered
A new study published in the Journal of the American Chemical Society showcases research from Purdue University on the development of an anticancer agent t...
OCT 16, 2019
Microbiology
OCT 16, 2019
A Canine Cancer That Began to Spread From One Dog About 6,000 Years Ago
Dogs can get different kinds of cancers, including one that is transmitted by live cancer cells, which spread through sexual contact....
OCT 16, 2019
Cell & Molecular Biology
OCT 16, 2019
Stopping Metastasis After Breast Cancer Surgery
Cancer is most deadly when it metastasizes, which can happen after tumor-removal surgery. It's a serious challenge for many patients....
OCT 16, 2019
Cardiology
OCT 16, 2019
Exercise Produces Greater Benefits In Those With Cardiovascular Disease
The fact that exercise benefits the heart and can help a person live a longer healthier life is well established. Exercising regularly can improve quality...
OCT 16, 2019
Cell & Molecular Biology
OCT 16, 2019
Stem Cell Derived Natural Killer T Cells as Novel and Long-term Cancer Treatment
Hematopoietic stem cells are used to create a population of Natural Killer T-cells that could sustain and renew within the immune system, and attack cancer cells....
OCT 16, 2019
Cardiology
OCT 16, 2019
What is Polycythemia Vera?
Polycythemia Vera (PV) is a slow-growing cancer of the blood. The cancer is characterized by an overproduction of blood cells within the bone marrow. Too m...
Loading Comments...